双鹭药业前三季度净利1.41亿元，同比增长943.1%

Core Viewpoint - Double-Crane Pharmaceutical (002038) reported a significant increase in net profit for the first three quarters of 2025, despite a decline in revenue, primarily due to gains from the fair value changes of financial assets held by the company [1] Financial Performance - The company achieved an operating revenue of 459 million yuan for the first three quarters, representing a year-on-year decrease of 15.13% [1] - The net profit attributable to shareholders reached 141 million yuan, showing a remarkable year-on-year increase of 943.1% [1] Asset Performance - The substantial growth in net profit is mainly attributed to the increase in fair value change gains from trading financial assets, including holdings in Shiyao Holdings and Xinghao Pharmaceutical [1] - For the period from January to September 2024, the company recognized a fair value change loss of 122 million yuan, while in the same period of 2025, it reported a fair value change gain of 128 million yuan, marking a year-on-year growth of 204.93% [1]